TRON in the News
2018
- Prof. Ugur Sahin erhält European Research Council (ERC) Advanced Grant 2017 für personalisierte Krebsimpfstoffe
- Prof. Ugur Sahin erhält ERC Advanced Grant 2017 für personalisierte Krebsimpfstoffe
- Forschungsförderung zur Entwicklung neuer Behandlungsansätze für neuroendokrine Tumoren
2017
- Nature News – Personalized cancer vaccines show glimmers of success
- Handelsblatt – Ein Impfstoff gegen den Krebs
- GenomeWeb – Personalized Cancer Vaccines Demonstrate Potential Melanoma Studies
- Transkript – Krebs: Biontechs Konzept funktioniert auch beim Menschen
- ResearchCareer – Custom cancer treatments tested
- Heise online – Neue Studien zeigen Wirksamkeit von individualisierten Krebs-Impfstoffen
- Spiegel – Jedem sein eigenes Medikament
- Technology Review – Erfolge mit individuellen Krebsimpfungen
- Trends der Zukunft – Personalisierte Krebsimpfung durchläuft erfolgreich erste klinische Studien
- Wired.it – Nuovi passi avanti per i vaccini personalizzati contro i tumori
- Popular Science – Personalized vaccines could help the immune system fight cancer
- Spektrum – Anfangserfolg für maßgeschneiderte Krebsimpfstoffe
- Aerzteblatt.de – Melanom: Personalisierte Impfstoffe erzielen langfristige Remissionen
- The Scientist – Personalized Cancer Vaccines Show Promise for Melanoma
- xconomy – Bio Roundup: BCRA Fireworks, Shkreli Muzzled, Endo Pulls Drug & More
- ars Technica – Custom cancer vaccines safely fight and kill tumors in early human trials
- ok salute – Tumori: inizia l’era dei vaccini terapeutici personalizzati
- RTL Nieuws – Veelbelovende test met vaccin tegen kanker
- FierceBiotech – Glimmers of hope for cancer vaccines as two neoantigen shots hit the mark
- Pharmazeutische Zeitung online – Melanome: Personalisierte Impfung bekämpft Krebs
- Le Scienze – Vaccini personalizzati contro il cancro
- HolaDoctor – Prueban con éxito dos vacunas contra el cáncer
- Cancer Research UK – Personalised vaccines to treat skin cancer show promise in small studies
- madrimasd – En busca de una vacuna contra cada cáncer
- Neue Zürcher Zeitung – Jedem seine eigene Krebsimpfung
- BioPortfolio – Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
- Sverige Radio – Forskning öppnar för skräddarsytt vaccin mot malignt melanom
- Biocentury – BioNTech, Neon teams report personalized cancer vaccine data
- Biotech Gate – Nature Publication Reports Favorable Clinical Trial Results of BioNTech’s Individualized Cancer Vaccine IVAC® MUTANOME
- nzDoctor.co.nz – Cancer: Personalised cancer vaccines show promise in initial human trials
- Yahoo News – Personalized vaccines hold cancer at bay in two early trials
- NEWSMAX – Personalized Vaccines Hold Cancer at Bay
- Channel NewAsia – Personalized vaccines hold cancer at bay in two early trials
- MSN noticias – En busca de una vacuna contra cada cáncer
- EL PAIS – En busca de una vacuna contra cada cáncer
- New Scientist – Cancer vaccines could prime our own bodies to fight tumours
- benzinga – Nature Publication Reports Favorable Clinical Trial Results of BioNTech’s Individualized Cancer Vaccine IVAC® MUTANOME
- FinanzNachrichten.de – BioNTech AG: Publikation in Nature berichtet über positive klinische Studienergebnisse mit BioNTechs individualisierter Krebsvakzine IVAC® MUTANOME
- FinanzNachrichten.de – BioNTech AG: Nature Publication Reports Favorable Clinical Trial Results of BioNTech’s Individualized Cancer Vaccine IVAC® MUTANOME
- Wallstreet:online – Nature Publication Reports Favorable Clinical Trial Results of BioNTech’s Individualized Cancer Vaccine IVAC® MUTANOME
- Newsweek – Cancer Breakthrough: Personalized Melanoma Vaccines ‘Safe and Effective’ in First Human Clinical Trials
- Yahoo News – Cancer Breakthrough: Personalized Melanoma Vaccines ‘Safe and Effective’ in First Human Clinical Trials
- Pettinga – Nature Publication Reports Favorable Clinical Trial Results of BioNTech’s Individualized Cancer Vaccine IVAC® MUTANOME
- Bild der Wissenschaft – Hautkrebs-Impfung im Test
- Nature Asia – Cancer: Personalized cancer vaccines show promise in initial human trials
- eCancer – Clinical trials provide proof-of-principle for personalised anti-cancer vaccines
2016
- Forscher arbeiten an einer Krebsimpfung
- FinanzNachrichten.de – Nature publication describes first example of a clinically applicable and systemic mRNA cancer immunotherapy vaccine
- Wallstreet online Deutschland – Nature Publication Describes First Example of a Clinically Applicable and Systemic mRNA Cancer Immunotherapy Vaccine
- Focus online – Neue Ära in der Krebstherapie: So bekämpft das Immunsystem erfolgreich Tumore
- Zeit online – Deutsche Forscher testen neue Immuntherapie gegen Krebs
- Bloomberg – Nature Publication Describes First Example of a Clinically Applicable and Systemic mRNA Cancer Immunotherapy Vaccine
- BioPortfolio – Nature Publication Describes First Example of a Clinically Applicable and Systemic mRNA Cancer Immunotherapy Vaccine
- International Business Time – Nanoparticles may be key to universal vaccine against cancer
- ecancer news – A step towards a universal cancer vaccine
- Biotech Gate – Nature Publication Describes First Example of a Clinically Applicable and Systemic mRNA Cancer Immunotherapy Vaccine
- The Australian – Cancer vaccine moves a step closer
- DNA India – Breakthrough: Researchers get one step closer to finding universal vaccine for cancer
- N-TV – Impfung gegen Krebs – Antigene wecken effektiv Immunsystem
- Becker’s Hospital Review – Researchers say immunotherapy method could lead to universal cancer vaccine
- Deutsches Ärzteblatt – Neuartige Krebsimpfung zeigt erste Wirkung bei Melanom-Patienten
- Allgemeine Zeitung – Schritt im Kampf gegen Krebs: Forscher aus Mainz entwickelt maßgeschneiderte Impfung
- AZ – Wissenschaftler setzen auf neuen Therapieansatz bei der Bekämpfung von Tumoren
2015
- ARD – Krebs: Fortschritte bei Immuntherapie
- BioWorld – BioNTech gives scientific rationale for personalized RNA cancer vaccines
- Spektrum – Rückt die maßgeschneiderte Immuntherapie gegen Krebs näher?
- SWR Rheinland-Pfalz – Report on vaccines against cancer
- Drug Target Review – New research describes blueprint for truly personalised cancer immunotherapies
- Science Media Centre – Expert reaction to study investigating cancer immunotherapy in mice
- The Independent – ‘Personalised’ cancer vaccine moves a step closer
- Huffington Post – Cancer Research Moves Towards Revolutionary Personalised Vaccines
- Health Day – Vaccine Spurs Immune Response to Fight Aggressive Cancers in Mice
- eCancerNews – Mouse models show tailored immunotherapy to be effective
- Medizin Aspekte – Auf dem Weg zu einer individualisierten Immuntherapie bei Krebs
- Fusion – Personalized cancer-fighting vaccines are on their way
- Jura Forum – Auf dem Weg zu einer individualisierten Immuntherapie bei Krebs
2014
- Translate and innovate. Dr Ugur Sahin explains the significance of the translational institute he established to accelerate the transition of biomarker-based cancer treatments from bench to bedside.
International Innovation. July 2014. (Courtesy of International Innovation – a leading scientific dissemination service)
2011
- Neues Spitzenforschungsinstitut in Mainz: TRON – Translationale Onkologie – Bindeglied zwischen Universität, Universitätsmedizin und Wirtschaft (February 2, 2010). Click here
Press Releases
- Official foundation ceremony of HI-TRON Mainz
- Cooperation agreements signed between TRON and DKFZ to found HI-TRON Mainz
- Prof. Ugur Sahin receives prestigious European Research Council (ERC) Advanced Grant for personalized cancer vaccines
- TRON receives three-year research grant from the Falconwood Foundation to develop new treatment approaches for neuroendocrine tumors
- TRON collaborates with its industrial partner BioNTech in a first-ever clinical study demonstrating that personalized RNA-based vaccines using mutant neo-epitopes as antigens activate immune system against individual mutations and exert anti-cancer activity. (July, 2017)
- TRON as a partner in a collaboration with industrial and academic experts in the field of immunology and cancer research, to develop, improve and optimize immunomodulatory concepts for increased efficacy and improved tolerability of cancer immunotherapies. (June, 2015)
- TRON is a partner in the newly established multi-partnered Horizon 2020 funded consortium APERIM, which will collaborate on the practical implementation of immunotherapy and the development of a new treatment platform specifically for unique tumour mutations of individual patients. (May 1, 2015)
- Auf dem Weg zu einer individualisierten Immuntherapie bei Krebs
Neue immunologische Erkenntnisse und technologische Fortschritte ebnen den Weg für maßgeschneiderte Krebsimpfstoffe / klinische Studie läuft bereits (March 23, 2015). - TRON and TheraCode together with Merck begin collaboration on identification and development of biomarkers for antigen-specific cancer immunotherapy (October 18, 2012).
- First preclinical proof-of-concept of mutation-based individualized cancer vaccine. Deep sequencing of immunogenic mutations may pave way for customized immunotherapy (Jan 17, 2012).
- New Variant Analysis Software from Ingenuity Used to Identify DNA Variants for Personalized Medicine Research (Jan 9, 2012).
- Der Brückenschlag: Translationale Medizin.
(© Das PDF zum Wissenschaftsmagazin dient lediglich der privaten Verwendung, es darf nicht kommerziell vervielfältigt und verbreitet werden. Alle Rechte liegen bei der Tempus Corporate GmbH) - New Convey Graph Constructor Leverages Hybrid-Core Architecture to Speed De Novo Genome Assembly (May 17, 2011).
- Next-generation sequencing technology for medicine and research in Mainz. Center for Translational Oncology and Immunology (TRON) Mainz has received one of the world’s first Illumina HiSeq genome sequencers (June 6, 2010).